• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2013 Fiscal Year Final Research Report

Blocking effect for percutaneous HIV infection by exposure of semen collected after oral administration of Maraviroc

Research Project

  • PDF
Project/Area Number 24791143
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Dermatology
Research InstitutionUniversity of Yamanashi

Principal Investigator

MATSUZAWA Takamitsu  山梨大学, 医学部附属病院, 医員 (40568028)

Project Period (FY) 2012-04-01 – 2014-03-31
KeywordsHIV感染予防法
Research Abstract

In light of the absence of a prophylactic vaccine, therapeutic strategies that reduce sexual transmission of HIV are urgently needed.
In this study, we evaluated whether exposure of semen collected after oral administration of Maraviroc (MVC), which is a orally available antagonist for CCR5 and has been clinically used for AIDS therapy, demonstrated potent blocking effect for HIV infection or not. We evaluated by using an ex vivo skin explant model. Even if volunteers were orally administrated MVC (600mg/day) for 1, 2, 3, or 14 days and then semen was collected, exposure of semen to epidermal sheets obtained from another volunteers had not significant blocking effect for HIV infection in epidermal LCs.

  • Research Products

    (1 results)

All 2013

All Journal Article (1 results) (of which Peer Reviewed: 1 results)

  • [Journal Article] Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium2013

    • Author(s)
      Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, Blauvelt A, Shimada S
    • Journal Title

      J Invest Dermatol

      Volume: 133(12) Pages: 2803-5

    • DOI

      10.1038/jid.2013.215

    • Peer Reviewed

URL: 

Published: 2015-06-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi